ATLANTA, GA - May 8, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor ...
GEO-CM04S1 demonstrated significantly enhanced T cell responses, specifically IFN-γ secretion and activation-induced markers (AIM+), compared to a matched cohort receiving an authorized mRNA vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback